In the past few days, the SASAC has adopted a series of measures to guide the relevant central enterprises to overcome difficulties, find ways to increase the production and supply of key medical prevention and control materials, and actively promote the research and development of new coronary pneumonia prevention and treatment drugs. On February 11, Hao Peng, Secretary of the Party Committee and Director of the State-owned Assets Supervision and Administration Commission and Leadership Team for the New Coronary Pneumonia Outbreak Work, went to Sinopec China Institute of Biology and other central enterprises to supply key medicine prevention and control materials for epidemic prevention and control production. Research progress.
Hao Peng emphasized that it is necessary to deeply implement the spirit of the important speech of General Secretary Jin Ping, who is investigating and guiding the prevention and control of new coronavirus pneumonia in Beijing, and in accordance with the unified deployment of the Party Central Committee and the State Council, insist on putting the safety and health of the people first Further promote the scientific spirit and innovative spirit, increase the research and development of new coronary pneumonia prevention and treatment drugs, and provide effective and effective support for epidemic prevention and control. Ren Hongbin, deputy director of the State-owned Assets Supervision and Administration Commission, member of the Party Committee, and deputy leader of the Leading Group for the New Coronary Pneumonia Outbreak Working Group, participated in related activities.
The key progress in the development of vaccines and effective drugs is crucial for epidemic prevention and control. At the National Institute of Biology, Sinopharm Group, Hao Peng listened to Liu Jingzhen, chairman of Sinopharm Group, on the supply of medical supplies, and Yang Xiaoming, chairman of China Biotechnology, reported on the progress of scientific research. He walked into the laboratory, checked the pilot workshop, communicated in depth with the scientific research personnel, learned about the progress of vaccine and therapeutic drug research and development, carefully listened to the opinions and suggestions of scientific research experts, and asked with concern what other problems, support and scientific arrangements R & D cycle, etc.
Hao Peng affirmed the role of the national team played by Sinopharm Group and China Biology in the fight against the new coronary pneumonia. He pointed out that China Bio Shanghai Jienuo took the lead in developing a new coronavirus nucleic acid detection reagent, which played an important role in patient screening. We must continue to optimize and innovate continuously, increase production and supply, and better meet the needs of epidemic prevention and control. We must respect the laws of science, race against time, compete with diseases and diseases, adhere to the combination of scientific research, clinical practice, and prevention and control, increase the research and development of new coronary pneumonia prevention and control drugs and vaccines, and strive to develop safe, effective and controllable drugs at an early date. Enhance the confidence of the whole society in defeating the epidemic.
Hu Jianwei, deputy general manager of Sinopharm Group, Zhu Jingjin, secretary of the Chinese Biological Party Committee, Wu Yonglin, president, Zhang Yuntao, vice president, the principals of China Biological Research Institute and Beijing Company participated in the survey.
Online
+86-18153515027
BackToTop